Clinical Trials

Clinical Study of PM01183 in Patients With Acute Leukemia

Location:

Rochester, MN

Trial status:

Open for Enrollment

Why is this study being done?

Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of PM01183 in Patients with Advanced Acute Leukemia to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 administered as 1-hour intravenous (i.v.) infusion on three consecutive days (Days 1-3) to patients with advanced acute leukemia and to assess the safety profile and tolerability, to obtain preliminary information on the efficacy and to characterize the pharmacokinetics (PK) and pharmacogenomic (PGx) profile of PM01183.

Last updated: 05/14/2013

NCT ID:

NCT01314599